Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870826 | 0.72 | ALDH1A1 (0.41) | FUCA1GLAMTNR1AMTNR1BENGASE | |
| SCHEMBL1860756 | 0.72 | FUCA1 (0.43) | FUCA1GLAMTNR1AMTNR1BENGASE | |
| SCHEMBL18535554 | 0.67 | FUCA1 (0.42) | FUCA1GLAMTNR1AENGASE | |
| SCHEMBL12019192 | 0.66 | FUCA1 (0.40) | FUCA1GLAMTNR1AMTNR1BENGASE | |
| SCHEMBL4663635 | 0.66 | — | — | |
| SCHEMBL2863034 | 0.66 | — | — | |
| SCHEMBL1863703 | 0.66 | FUCA1 (0.38) | FUCA1GLAMTNR1ANPSR1FAP | |
| SCHEMBL23969067 | 0.65 | FUCA1 (0.41) | FUCA1GLAMTNR1AENGASE | |
| SCHEMBL14192097 | 0.63 | SMN1; SMN2 (0.38) | FUCA1GLAMTNR1ANPSR1FAP | |
| SCHEMBL31677770 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | CD40, LITAF, TNF | FUCA1 1655/4885GLA 3535/4885MTNR1A 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.